Wedbush Reiterates Outperform on Karuna Therapeutics, Maintains $253 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $253.
November 17, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Karuna Therapeutics with a steady price target of $253, indicating a positive outlook for the stock.
The reiteration of an Outperform rating by a reputable analyst like Laura Chico from Wedbush is a strong positive signal for investors, suggesting that the analyst has a continued bullish outlook on the stock. The maintenance of a high price target of $253 implies that the analyst believes the stock has significant upside potential from its current level. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100